Diabetic Neuropathy Market by Treatment Type (Drugs, Physiotherapy), Disorder Type (Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy), Distribution channel - Global Forecast 2024-2030
The Diabetic Neuropathy Market size was estimated at USD 3.50 billion in 2023 and expected to reach USD 3.72 billion in 2024, at a CAGR 6.37% to reach USD 5.40 billion by 2030.
Diabetic neuropathy is a medical condition that damages the nerve and occurs in patients who have diabetes. High blood sugar (glucose) can damage nerves throughout the body, and diabetic neuropathy most frequently impacts nerves in the legs and feet. The increasing need for effective treatment for diabetic neuropathy, diagnosis of diabetes, and several government initiatives are the major driving factors for the growth of the diabetic neuropathy market. In addition, the growing awareness about diabetic neuropathy, increased healthcare spending, and a rise in pharmaceutical R&D spending contribute to developing novel drugs and systems for treating diabetic neuropathy. However, the high cost of medications used to treat diabetic neuropathy and the availability of alternative therapies may limit their use by diabetic patients. Production of advanced drug delivery systems and rising research in diabetic neuropathy are leading to the development of a breakthrough system for the effective management of diabetic neuropathy conditions, accelerating their use by patients in the forecast period.
Regional Insights
The Americas has a significant market in diabetic neuropathy due to the presence of a rising number of diabetic patients and increasing awareness related to diabetes disorders. Approvals from the FDA for new product development and ongoing research activities for developing novel and effective drugs are major growth factors in the Americas region. The Asia-Pacific region represents a growing landscape for the global diabetic neuropathy market due to increasing R&D activities in drug development. Several start-ups focusing on developing diabetic neuropathy treatments in the APAC region have contributed to the market growth. Government support to raise awareness regarding diabetes management and increased research and development of novel drugs and systems for relieving pain and efficient management of diabetic neuropathy conditions are creating the immense potential for the deployment of diabetic neuropathy drugs and systems in the EMEA region. Additionally, the introduction of innovative treatments and drug delivery systems is expected to contribute to the growth of the diabetic neuropathy market worldwide.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Diabetic Neuropathy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rising prevalence of diabetic neuropathy and the need for effective treatment methods
- Increasing awareness pertaining to diagnosis & treatment of diabetes
- Government initiatives for the management of diabetic neuropathy
- Market Restraints
- High failure rate in clinical trials and high cost of diabetic neuropathy treatment
- Market Opportunities
- Widening diabetic neuropathy research areas
- Development of advanced drug delivery systems
- Market Challenges
- Complications associated with diabetic neuropathy treatment
- Market Segmentation Analysis
- Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
- Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
- Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Diabetic Neuropathy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Diabetic Neuropathy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
NeuraLace Medical, Inc. announced the completion of enrollment in the AT-PDN study, which involved randomizing 70 patients into treatment and sham groups. This development represents a potential breakthrough in the treatment of PDN, with the potential to benefit millions of patients.
GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
Scientists from the University of Liverpool and Manchester Metropolitan University have received funding of GBP 1.4 million to develop an early test for Diabetic Peripheral Neuropathy (DPN). The project involves collaboration between university investigators and partners such as Aintree University Hospital and Weill Cornell Medicine, funded by the Engineering & Physical Sciences Research Council (EPSRC) for over GBP 1 million.
Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
Horizon Therapeutics PLC, a biopharmaceutical company focused on creating innovative medicines to enable people to live better lives, received an update from the United States Food and Drug Administration (FDA) regarding the approval of their drug, Tepezza. This drug has already been approved for treating thyroid eye disease and is now considered for treating diabetic neuropathy as well.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Diabetic Neuropathy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Diabetic Neuropathy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AdventHealth, Alkem Labs, Astellas Pharma Inc., AstraZeneca PLC, Bauerfeind AG, Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Collegium Pharmaceutical, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grünenthal GmbH, Harmonium Pharma s.r.l., Lupin Limited, Medtronic PLC, Merck KGaA, NeuroMetrix, Inc., Nevro Corp., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Praetego, LLC, Regenacy Pharmaceuticals, Inc., Sanofi S.A., Stem Cell Care India, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Trevena, Inc., Vertex Pharmaceuticals Incorporated, Viatris Inc., and Winsantor, Inc..
Market Segmentation & Coverage
This research report categorizes the Diabetic Neuropathy Market to forecast the revenues and analyze trends in each of the following sub-markets:- Treatment Type
- Drugs
- Analgesics
- Non-Steroidal Anti-Inflammatory Drugs
- Opioids
- Topical
- Anticonvulsants
- Gabapentin
- Pregabalin
- Topiramate
- Antidepressant
- Serotonin & Norepinephrine Reuptake Inhibitors
- SSRIs
- TCAs
- Physiotherapy
- Disorder Type
- Autonomic Neuropathy
- Focal Neuropathy
- Peripheral Neuropathy
- Proximal Neuropathy
- Distribution channel
- Clinics
- Hospitals
- Online Pharmacy
- Retail Pharmacy
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Analgesics
- Drugs
- Market Drivers
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
- 5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
- 5.1.1.3. Government initiatives for the management of diabetic neuropathy
- 5.1.2. Restraints
- 5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
- 5.1.3. Opportunities
- 5.1.3.1. Widening diabetic neuropathy research areas
- 5.1.3.2. Development of advanced drug delivery systems
- 5.1.4. Challenges
- 5.1.4.1. Complications associated with diabetic neuropathy treatment
- 5.2. Market Segmentation Analysis
- 5.2.1. Treatment Type: Wide use of drugs for pharmacological treatment in diabetic neuropathy for alleviating pain and stabilizing nerve function
- 5.2.2. Disorder Type: Preference for diabetic neuropathy due to increasing prevalence of peripheral neuropathy
- 5.2.3. Distribution channel: Emergence of online pharmacies as a convenient distribution channel for medications prescribed for diabetic neuropathy management
- 5.3. Market Trend Analysis
- 5.3.1. Ongoing research for the development of novel treatments and rise in approvals for diabetic neuropathy management systems in the Americas
- 5.3.2. Increasing prevalence of diabetes and emerging start-ups focused on developing diabetic neuropathy treatments and devices in the APAC region
- 5.3.3. Supportive government initiatives to improve diabetes disease treatment and care in the EMEA region
- 5.4. Cumulative Impact of Russia-Ukraine Conflict
- 5.5. Cumulative Impact of High Inflation
- 5.6. Porter’s Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
- 5.7. Value Chain & Critical Path Analysis
- 5.8. Regulatory Framework Analysis
- 6. Diabetic Neuropathy Market, by Treatment Type
- 6.1. Introduction
- 6.2. Drugs
- 6.3. Physiotherapy
- 7. Diabetic Neuropathy Market, by Disorder Type
- 7.1. Introduction
- 7.2. Autonomic Neuropathy
- 7.3. Focal Neuropathy
- 7.4. Peripheral Neuropathy
- 7.5. Proximal Neuropathy
- 8. Diabetic Neuropathy Market, by Distribution channel
- 8.1. Introduction
- 8.2. Clinics
- 8.3. Hospitals
- 8.4. Online Pharmacy
- 8.5. Retail Pharmacy
- 9. Americas Diabetic Neuropathy Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Diabetic Neuropathy Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Diabetic Neuropathy Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.3.1. Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
- 12.3.2. GBP 1.4 million Awarded to Create early test for Diabetic Peripheral Neuropathy
- 12.3.3. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
- 12.3.4. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
- 12.3.5. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment
- a diabetic for diabetic
- 12.3.6. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
- 12.3.7. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
- 12.3.8. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
- 12.3.9. Glenmark Pharma launched drug for diabetic patients with comorbidities
- 12.3.10. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
- 12.3.11. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
- 12.3.12. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy
- 12.3.13. FDA cleared Medtronic's neurostimulator for diabetic peripheral neuropathy pain
- 12.3.14. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
- 12.3.15. Withings acquired Devicemaker Impeto Medical
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.2. Key Product Portfolio
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook